# US 2017/0283775 A1 · Compositions and Methods for Treatment of Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283775 A1
- Document ID: US20170283775A1
- Status: Published application
- Kind: A1
- Application number: 15/353,899
- Filed: 2016-11-17
- Published: 2017-10-05
- Earliest claimed: 2010-12-09
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Carl H. June; Bruce L. Levine; David L. Porter; Michael D. Kalos; Michael C. Milone
- Web page: https://patentgrep.com/patent/US20170283775A1

## CPC

- C12N 5/0636: {T lymphocytes}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/4211: {CD19 or B4}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/075: Adenoviridae
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70517: {CD8}
- C07K 14/70521: {CD28, CD152}
- C07K 14/70578: {NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95 (NGF-receptor C07K14/71, TNF-receptor C07K14/7151)}
- C07K 14/70596: {Molecules with a "CD"-designation not provided for elsewhere}
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- C07K 16/30: from tumour cells
- C07K 16/3061: {Blood cells}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/85: for animal cells
- C12N 15/861: Adenoviral vectors
- A61K 2039/505: {comprising antibodies}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/585: {wherein the target is cancer}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- C07K 2317/53: Hinge
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/80: remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2501/515: CD3, T-cell receptor complex
- C12N 2510/00: Genetically modified cells
- C12N 2740/15034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- C12N 2740/15071: Demonstrated in vivo effect
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.

## Claims

### Claim 1

A human memory T cell comprising a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the human memory T cell is of a human having cancer.

### Claim 2 (depends on 1)

The human memory T cell of claim 1, wherein the CD19 antigen binding domain is a Fab or scFv.

### Claim 3 (depends on 2)

The human memory T cell of claim 2, wherein the CD19 antigen binding domain is a scFv.

### Claim 4 (depends on 1)

The human memory T cell of claim 1, wherein the transmembrane domain comprises CD8 transmembrane domain.

### Claim 5 (depends on 1)

The human memory T cell of claim 1, wherein the co-stimulatory signaling region is CD27 or 4-1BB.

### Claim 6 (depends on 1)

The human memory T cell of claim 1, wherein the CAR further comprises a hinge region.

### Claim 7 (depends on 6)

The human memory T cell of claim 6, wherein the hinge region comprises a CD8α hinge region.

### Claim 8

A human memory T cell comprising a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the human memory T cell is of a human having cancer.

### Claim 9 (depends on 8)

The human memory T cell of claim 8, wherein the CD19 antigen binding domain is a Fab or scFv.

### Claim 10 (depends on 9)

The human memory T cell of claim 9, wherein the CD19 antigen binding domain is a scFv.

### Claim 11 (depends on 8)

The human memory T cell of claim 8, wherein the transmembrane domain comprises CD8 transmembrane domain.

### Claim 12 (depends on 8)

The human memory T cell of claim 8, wherein the co-stimulatory signaling region is CD27 or 4-1BB.

### Claim 13 (depends on 8)

The human memory T cell of claim 8, wherein the CAR further comprises a hinge region.

### Claim 14 (depends on 13)

The human memory T cell of claim 13, wherein the hinge region comprises a CD8α hinge region.

### Claim 15

A persisting population of human T cells comprising a nucleic acid sequence that encodes a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human having cancer.

### Claim 16 (depends on 15)

The persisting population of human T cells of claim 15, wherein the CD19 antigen binding domain is a Fab or scFv.

### Claim 17 (depends on 16)

The persisting population of human T cells of claim 16, wherein the CD19 antigen binding domain is a scFv.

### Claim 18 (depends on 15)

The persisting population of human T cells of claim 15, wherein the transmembrane domain comprises CD8 transmembrane domain.

### Claim 19 (depends on 15)

The persisting population of human T cells of claim 15, wherein the co-stimulatory signaling region is CD27 or 4-1BB.

### Claim 20 (depends on 15)

The persisting population of human T cells of claim 15, wherein the CAR further comprises a hinge region.

### Claim 21 (depends on 20)

The persisting population of human T cells of claim 20, wherein the hinge region comprises a CD8α hinge region.

### Claim 22

A persisting population of human T cells comprising a chimeric antigen receptor (CAR), wherein the CAR comprises a CD19 antigen binding domain, a transmembrane domain, a co-stimulatory signaling region and a CD3 zeta signaling domain, wherein the persisting population of T cells are of a human having cancer.

### Claim 23 (depends on 22)

The persisting population of human T cells of claim 22, wherein the CD19 antigen binding domain is a Fab or scFv.

### Claim 24 (depends on 23)

The persisting population of human T cells of claim 23, wherein the CD19 antigen binding domain is a scFv.

### Claim 25 (depends on 22)

The persisting population of human T cells of claim 22, wherein the transmembrane domain comprises CD8 transmembrane domain.

### Claim 26 (depends on 22)

The persisting population of human T cells of claim 22, wherein the co-stimulatory signaling region is CD27 or 4-1BB.

### Claim 27 (depends on 22)

The persisting population of human T cells of claim 22, wherein the CAR further comprises a hinge region.

### Claim 28 (depends on 27)

The persisting population of human T cells of claim 27, wherein the hinge region comprises a CD8α hinge region.
